Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Visa to Move European Headquarters to London’s Canary Wharf 
Pompano Beach, Fla., Dec. 09, 2015 (GLOBE NEWSWIRE) -- DS Healthcare Group’s flagship products are now selling in Walmart, one of Brazil’s largest retailers. With this addition, DS Laboratories further expands its global retail footprint as part of the company’s omni-channel approach and continued dedication to delivering its breakthroughs to consumers worldwide.
Brazilian customers can view our product selection and order at the following link: https://www.walmart.com.br/busca/?ft=ds+laboratories&PS=20
Brazil remains the world's third largest consumer market for toiletries and stands as the world’s second largest market for men’s and children’s hair care products. The partnership with Walmart is expected to drive significant revenue growth for the company in Brazil.
About DS Healthcare Group
DS Healthcare Group Inc. is a leader in the development of biotechnology for topical therapies. It markets through online channels, specialty retailers, distributors, pharmacies, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com or www.facebook.com/DS.Labs
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov
Investor Relations DS Healthcare Group (888) 404-7770 ext. 3 [email protected]
